Prostate Cancer Clinical Trial
Ga-68 MAA Distribution in PAE Patients
Summary
Purpose: The purpose of this study is to evaluate Ga-68 MAA distribution on PET/MRI after injection into the prostatic arteries in patients without prostate cancer who are being treated with prostate artery embolization for benign prostatic hyperplasia.
Participants: Study subjects will be 5 men scheduled to undergo the PAE procedure at UNC Hospital for benign prostatic hyperplasia.
Procedures (methods): Study subjects will undergo PAE using the standard technique. Prior to embolization of the prostatic artery with the bland embolic agent, Ga-68 MAA will be injected. Standard departmental radiation protection procedures will be followed. After the PAE procedure is complete, the patient will be transported to the UNC Biomedical Research Imaging Center to undergo PET/MRI.
Full Description
This study is an initial proof of concept evaluation to determine the feasibility of using Y-90 radioembolization performed using the Sniper balloon occlusion microcatheter to treat localized prostate cancer. This will be performed by evaluating Ga-68 MAA distribution on PET/MRI after injection into the prostatic arteries in patients without prostate cancer who are being treated with prostate artery embolization for benign prostatic hyperplasia. The distribution of the radiotracer activity within the prostate and any activity in adjacent organs will be determined for when the tracer is injected into the central prostatic arteries.
Eligibility Criteria
Inclusion Criteria:
Male
Age > 40
Prostate gland >50 grams as measured by pre-procedural CTA
Have previously taken BPH medication for 6 months without desired improvement of LUTS or has started medication and stopped due to unwanted side effects
Moderate to severe LUTS as defined by IPSS score >18
Peak urine flow rate (Qmax) <12 mL/sec
Capable of giving informed consent
Life expectancy greater than 1 year
Exclusion Criteria:
Severe vascular disease
Uncontrolled diabetes mellitus
Immunosuppression
Unable to lie flat, still or tolerate a PET/MRI scan.
Neurogenic bladder and/or sphincter abnormalities secondary to Parkinson's disease, multiple sclerosis, cerebral vascular accident, diabetes, etc.
Complete urinary retention
Impaired kidney function (serum creatinine level > 1.8 mg/dl or a glomerular filtration rate < 60 as approximated using serum creatinine levels) unless anuric and on dialysis.
Confirmed or suspected bladder cancer
Urethral strictures, bladder neck contracture, or other potentially confounding bladder pathology
Ongoing urogenital infection
Previous pelvic radiation or radical pelvic surgery
Confirmed or suspected malignancy of the prostate based on DRE, TRUS or PSA (> 10 ng/mL or > 4.0 ng/mL and < 10 ng/mL with free PSA < 25% of total PSA without a negative biopsy).
Uncorrectable coagulopathy including INR > 1.5 or platelets < 50,000
Contrast hypersensitivity refractory to standard medications (antihistamines, steroids)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Chapel Hill North Carolina, 27599, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.